GB0820819D0 - Pharmaceutical compounds - Google Patents

Pharmaceutical compounds

Info

Publication number
GB0820819D0
GB0820819D0 GBGB0820819.1A GB0820819A GB0820819D0 GB 0820819 D0 GB0820819 D0 GB 0820819D0 GB 0820819 A GB0820819 A GB 0820819A GB 0820819 D0 GB0820819 D0 GB 0820819D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical compounds
pharmaceutical
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0820819.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sareum Ltd
Original Assignee
Sareum Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sareum Ltd filed Critical Sareum Ltd
Priority to GBGB0820819.1A priority Critical patent/GB0820819D0/en
Publication of GB0820819D0 publication Critical patent/GB0820819D0/en
Priority to PCT/GB2009/002662 priority patent/WO2010055304A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0820819.1A 2008-11-13 2008-11-13 Pharmaceutical compounds Ceased GB0820819D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0820819.1A GB0820819D0 (en) 2008-11-13 2008-11-13 Pharmaceutical compounds
PCT/GB2009/002662 WO2010055304A2 (en) 2008-11-13 2009-11-13 Pharmaceutical compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0820819.1A GB0820819D0 (en) 2008-11-13 2008-11-13 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
GB0820819D0 true GB0820819D0 (en) 2008-12-24

Family

ID=40194606

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0820819.1A Ceased GB0820819D0 (en) 2008-11-13 2008-11-13 Pharmaceutical compounds

Country Status (2)

Country Link
GB (1) GB0820819D0 (en)
WO (1) WO2010055304A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2250160B1 (en) 2008-01-25 2015-11-11 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CN102395585A (en) 2009-01-30 2012-03-28 米伦纽姆医药公司 Heteroaryls and their use as pi3k inhibitors
EP2603216A4 (en) 2010-08-11 2013-12-18 Millennium Pharm Inc Heteroaryls and uses thereof
CA2807971A1 (en) 2010-08-11 2012-02-16 Millenium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
AR083450A1 (en) 2010-10-13 2013-02-27 Millennium Pharm Inc HETEROARILOS AND ITS USES IN THE TREATMENT OF PROLIFERATIVE, INFLAMMATORY OR CARDIOVASCULAR DISEASES
WO2012075393A2 (en) * 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
GB201202027D0 (en) * 2012-02-06 2012-03-21 Sareum Ltd Pharmaceutical compounds
EP2634185B1 (en) 2012-03-02 2016-01-13 Sareum Limited TYK2 kinase inhibitors
GEP201706748B (en) 2012-08-10 2017-10-10 Boehringer Ingelheim Int Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
CN103848810A (en) 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 Bruton's tyrosine kinases inhibitor
US8895750B2 (en) 2013-03-14 2014-11-25 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as BTK inhibitors
EP2970300B1 (en) 2013-03-15 2018-05-16 Boehringer Ingelheim International GmbH Heteroaromatic compounds as btk inhibitors
WO2015032423A1 (en) 2013-09-03 2015-03-12 Sareum Limited Pharmaceutical compounds
EP3052476B1 (en) 2013-09-30 2020-07-15 Guangzhou InnoCare Pharma Tech Co., Ltd. Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
EP3099674B1 (en) 2014-01-29 2018-10-24 Boehringer Ingelheim International Gmbh Pyrazole compounds as btk inhibitors
US10000474B2 (en) 2014-11-11 2018-06-19 Musc Foundation For Research Development Histone deacetylase inhibitors and uses thereof
DK3390390T3 (en) 2015-12-16 2021-12-06 Boehringer Ingelheim Int Bipyrazolyl derivatives suitable for the treatment of autoimmune diseases
WO2017123695A1 (en) 2016-01-13 2017-07-20 Boehringer Ingelheim International Gmbh Isoquinolones as btk inhibitors
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
GB201816369D0 (en) 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds
SG11202112043PA (en) 2019-04-30 2021-11-29 Celgene Corp Combination therapies comprising apremilast and tyk2 inhibitors
GB202005114D0 (en) 2020-04-07 2020-05-20 Sareum Ltd Crystalline Forms of a Pharmaceutical Compound
CN117396465A (en) * 2021-06-01 2024-01-12 阿斯克里斯有限公司 Novel oxazole derivative for preventing or treating allergic diseases and pharmaceutical composition containing the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61155456A (en) 1984-12-27 1986-07-15 Fujikura Rubber Ltd Electromagnetic wave shielding composition
JPH0753716B2 (en) 1986-07-02 1995-06-07 吉富製薬株式会社 Imidazol carboxamide derivative
SK18102002A3 (en) 2000-06-28 2003-07-01 Astrazeneca Ab Substituted quinazoline derivatives, their use and a composition comprising said derivatives
US6884889B2 (en) 2002-03-25 2005-04-26 Bristol-Myers Squibb Co. Processes for the preparation of antiviral 7-azaindole derivatives
US7361665B2 (en) 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
JP2006525320A (en) * 2003-05-08 2006-11-09 アステラス製薬株式会社 COX inhibitor
GB0321648D0 (en) 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
CA2542909C (en) 2003-10-23 2012-07-10 Ab Science 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
US7652035B2 (en) 2004-10-19 2010-01-26 Neurocrine Bioscience, Inc. CRF receptor antagonists and methods relating thereto
GB0504753D0 (en) 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
WO2007043401A1 (en) 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
WO2007131953A1 (en) 2006-05-12 2007-11-22 Ab Science A new process for the synthesis of 2-aminoxazole compounds
US20090093452A1 (en) 2006-08-24 2009-04-09 Pfizer Inc. Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives
GB0709031D0 (en) * 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
WO2010055304A3 (en) 2010-07-08
WO2010055304A2 (en) 2010-05-20

Similar Documents

Publication Publication Date Title
ZA201104336B (en) Pharmaceutical compounds
GB0816372D0 (en) Pharmaceutical compounds
IL237391A0 (en) Pharmaceutical combination
GB0820819D0 (en) Pharmaceutical compounds
GB0801416D0 (en) Pharmaceutical compounds
GB0709031D0 (en) Pharmaceutical compounds
IL201366A0 (en) Pharmaceutical compounds
GB0721095D0 (en) Pharmaceutical compounds
GB0816371D0 (en) Pharmaceutical compounds
GB0707087D0 (en) Pharmaceutical compounds
GB0810615D0 (en) Novel pharmaceutical
GB0725214D0 (en) Pharmaceutical compounds
GB0812969D0 (en) Pharmaceutical compounds
PL2271618T3 (en) Pharmaceutical compounds
GB0816370D0 (en) Pharmaceutical compounds
GB0704932D0 (en) Pharmaceutical compounds
GB0721669D0 (en) Pharmaceutical compounds
HK1152640A1 (en) Pharmaceutical combination
GB0810857D0 (en) Pharmaceutical compounds
GB0810617D0 (en) Novel pharmaceutical
HU0800414D0 (en) Pharmaceutical combination
GB0820825D0 (en) Pharmaceutical compounds
GB0805300D0 (en) Pharmaceutical compounds
GB0820820D0 (en) Pharmaceutical compounds
GB0817006D0 (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)